Millennium Management’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-8,724
| Closed | -$102K | – | 7043 |
|
|
2023
Q1 | $102K | Sell |
8,724
-1,147
| -12% | -$19.1K | ﹤0.01% | 5425 |
|
|
2022
Q4 | $151K | Buy |
9,871
+360
| +4% | +$4.2K | ﹤0.01% | 5438 |
|
|
2022
Q3 | $57K | Sell |
9,511
-6,064
| -39% | -$50.7K | ﹤0.01% | 6144 |
|
|
2022
Q2 | $145K | Buy |
15,575
+13,529
| +661% | +$240K | ﹤0.01% | 5782 |
|
|
2022
Q1 | $66K | Sell |
2,046
-2,502
| -55% | -$98.4K | ﹤0.01% | 6316 |
|
|
2021
Q4 | $217K | Buy |
4,548
+2,512
| +123% | +$173K | ﹤0.01% | 5849 |
|
|
2021
Q3 | $187K | Buy |
2,036
+372
| +22% | +$30.9K | ﹤0.01% | 6153 |
|
|
2021
Q2 | $159K | Sell |
1,664
-89
| -5% | -$7.78K | ﹤0.01% | 6104 |
|
|
2021
Q1 | $171K | Buy |
+1,753
| New | +$215K | ﹤0.01% | 5537 |
|
|
2020
Q4 | – | Sell |
-264
| Closed | -$16 | – | 5716 |
|
|
2020
Q3 | $16 | Sell |
264
-5,162
| -95% | -$389K | ﹤0.01% | 4359 |
|
|
2020
Q2 | $478K | Buy |
5,426
+3,785
| +231% | +$400K | ﹤0.01% | 3435 |
|
|
2020
Q1 | $184K | Buy |
1,641
+1,466
| +838% | +$289K | ﹤0.01% | 3418 |
|
|
2019
Q4 | $43K | Sell |
175
-204
| -54% | -$51.5K | ﹤0.01% | 4107 |
|
|
2019
Q3 | $130K | Buy |
+379
| New | +$206K | ﹤0.01% | 3906 |
|
|
2019
Q2 | – | Sell |
-264
| Closed | -$420K | – | 4613 |
|
|
2019
Q1 | $420K | Sell |
264
-6,097
| -96% | -$11M | ﹤0.01% | 3378 |
|
|
2018
Q4 | $11.9M | Sell |
6,361
-38
| -0.6% | -$82.7K | 0.02% | 1022 |
|
|
2018
Q3 | $15.1M | Buy |
6,399
+965
| +18% | +$2.99M | 0.02% | 1021 |
|
|
2018
Q2 | $18.7M | Sell |
5,434
-689
| -11% | -$2.11M | 0.02% | 899 |
|
|
2018
Q1 | $17.4M | Buy |
6,123
+4,466
| +270% | +$13.4M | 0.02% | 961 |
|
|
2017
Q4 | $4.26M | Buy |
+1,657
| New | +$4.71M | 0.01% | 1814 |
|
|
2017
Q3 | – | Sell |
-1,660
| Closed | -$3.92M | – | 3974 |
|
|
2017
Q2 | $3.92M | Sell |
1,660
-111
| -6% | -$220K | 0.01% | 1670 |
|
|
2017
Q1 | $4.46M | Sell |
1,771
-2,325
| -57% | -$6.69M | 0.01% | 1524 |
|
|
2016
Q4 | $9.24M | Buy |
4,096
+2,030
| +98% | +$4.83M | 0.02% | 972 |
|
|
2016
Q3 | $5.18M | Sell |
2,066
-2,648
| -56% | -$7.9M | 0.01% | 1320 |
|
|
2016
Q2 | $14.4M | Buy |
4,714
+440
| +10% | +$1.43M | 0.03% | 674 |
|
|
2016
Q1 | $13.6M | Buy |
4,274
+7
| +0.2% | +$29.1K | 0.03% | 660 |
|
|
2015
Q4 | $21.9M | Sell |
4,267
-2,723
| -39% | -$11.9M | 0.05% | 540 |
|
|
2015
Q3 | $22.2M | Buy |
6,990
+3,545
| +103% | +$13.7M | 0.04% | 518 |
|
|
2015
Q2 | $13.8M | Sell |
3,445
-3,631
| -51% | -$14M | 0.03% | 799 |
|
|
2015
Q1 | $28.3M | Buy |
7,076
+5,665
| +401% | +$25.9M | 0.05% | 487 |
|
|
2014
Q4 | $6.92M | Sell |
1,411
-954
| -40% | -$4.09M | 0.01% | 1194 |
|
|
2014
Q3 | $9.61M | Sell |
2,365
-3,515
| -60% | -$13.2M | 0.02% | 886 |
|
|
2014
Q2 | $23.8M | Buy |
+5,880
| New | +$24M | 0.07% | 400 |
|
|
2014
Q1 | – | Sell |
-2,081
| Closed | -$7.29M | – | 3987 |
|
|
2013
Q4 | $7.29M | Buy |
2,081
+1,291
| +163% | +$5.03M | 0.02% | 912 |
|
|
2013
Q3 | $3.24M | Sell |
790
-277
| -26% | -$1.19M | 0.01% | 1384 |
|
|
2013
Q2 | $4.23M | Buy |
+1,067
| New | +$4.39M | 0.01% | 1129 |
|
Other funds holding ACOR
DKCM
Millennium Management's ACOR Position: Q2 2023 in Review
Millennium Management sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 8,724 shares — an estimated $102K sold.
Millennium Management first reported a position in ACOR in Q2 2013 and held it in 36 quarters. The position peaked at $28.3M in Q1 2015. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.
- Millennium Management reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
- Millennium Management sold 8,724 Acorda Therapeutics shares in Q2 2023, an estimated $102K.
- Millennium Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 36 quarters.
- Millennium Management's Acorda Therapeutics position peaked at $28.3M in Q1 2015.
- 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.
Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.